This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dunn, G. Articles by Tomenson, B. Search for Related Content PubMed PubMed Citation Articles by Dunn, G. Articles by Tomenson, B. Social Bookmarking                         What's this?

Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods

Biostatistics Group, University of Manchester, UK, graham.dunn{at}manchester.ac.uk

Mohammad Maracy

Biostatistics Group, University of Manchester, UK and Medical Faculty, University of Isfahan, Iran

Barbara Tomenson

Division of Psychiatry, School of Medicine, University of Manchester, UK

Perfectly implemented randomized clinical trials, particularly of complex interventions, are extremely rare. Almost always they are characterized by imperfect adherence to the randomly allocated treatment and variable amounts of missing outcome data. Here we start by describing a wide variety of examples and then introduce instrumental variable methods for the analysis of such trials. We concentrate mainly on situations in which compliance is all or nothing (either the patient receives the allocated treatment or they do not - in the latter case they may receive no treatment or a treatment other than the one allocated). The main purpose of the review is to illustrate the use of latent class (finite mixture) models, using maximum likelihood, for complier-average causal effect estimation under varying assumptions concerning the mechanism of the missing outcome data.

Statistical Methods in Medical Research, Vol. 14, No. 4, 369-395 (2005)
DOI: 10.1191/0962280205sm403oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Xia, C. Adams, N. Bhagat, V. Bhagat, P. Bhoopathi, H. El-Sayeh, V. Pinfold, and Y. Takriti Losing participants before the trial ends erodes credibility of findings Psychiatr. Bull., July 1, 2009; 33(7): 254 - 257. [Abstract] [Full Text] [PDF]

				S. Greenland, S. Lanes, and M. Jara Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation Clinical Trials, February 1, 2008; 5(1): 5 - 13. [Abstract] [PDF]

				S. W. Lewis, T. R. E. Barnes, L. Davies, R. M. Murray, G. Dunn, K. P. Hayhurst, A. Markwick, H. Lloyd, and P. B. Jones Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia Schizophr Bull, October 1, 2006; 32(4): 715 - 723. [Abstract] [Full Text] [PDF]

				C. E. Hewitt, D. J. Torgerson, and J. N.V. Miles Is there another way to take account of noncompliance in randomized controlled trials? Can. Med. Assoc. J., August 15, 2006; 175(4): 347 - 347. [Full Text] [PDF]

				E. Goetghebeur and S. Vansteelandt Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of exposure Statistical Methods in Medical Research, August 1, 2005; 14(4): 397 - 415. [Abstract] [PDF]